Home / Peptides / Teriparatide
Teriparatide: FDA status and clinical evidence
Teriparatide is approved by the FDA and is on the US market, first approved November 26, 2002, under 7 applications. 182 studies are registered on ClinicalTrials.gov, reaching Phase 4.
FDA approval status
FDA review documents
Clinical evidence
By phase
Patents and generic availability
Molecular identity
10T9CSU89ISVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFFrom the FDA Global Substance Registration System, the registry that assigns every substance the FDA tracks a unique identifier.
Frequently asked questions
Is Teriparatide FDA-approved?
Yes. Teriparatide holds FDA approval and is marketed in the US. Approval covers the specific uses, doses and forms on the FDA label, not every use it is sold or discussed for.
How much clinical research is there on Teriparatide?
182 studies are registered on ClinicalTrials.gov with Teriparatide as an intervention, 114 of them completed. The highest phase reached is Phase 4. Registration counts research activity, not proven benefit.
What brand names is Teriparatide sold under?
FDA records list BONSITY, FORTEO, PARATHAR, TERIPARATIDE. Brand availability changes over time, and some applications on file are marked discontinued.
Where does the information on this page come from?
Four FDA and NIH sources: Drugs@FDA for approval records, the FDA Orange Book for patents and exclusivity, the FDA Global Substance Registration System for molecular identity, and ClinicalTrials.gov for trial counts. Each is refreshed on a schedule and the date above shows the last refresh.
Sources: Drugs@FDA, FDA Orange Book, FDA Global Substance Registration System and ClinicalTrials.gov. Last refreshed 2026-10-16.